How many drugs are losing patent protection in 2034?

Drug Landscape tracks 52 marketed drugs with at least one patent expiring in 2034, sourced from FDA Orange Book + USPTO Patent Public Search.

What is a patent cliff?

A patent cliff is the year a major branded drug loses primary patent protection, opening the market to generic or biosimilar entry. Originator revenue typically drops 30–80% within 24 months, depending on the drug class and the strength of secondary patents.

Are these forecasts accurate?

Patent expiry dates are deterministic — they're the listed expiry from the Orange Book or USPTO record. Generic / biosimilar entry timing depends on litigation outcomes, paragraph IV challenges, settlements, and exclusivity periods which can shift the practical "cliff" by months to years.

Last reviewed 2026-05-15 · How we verify

2034 Pharmaceutical Patent Cliff

52 marketed drugs with patents expiring in 2034, joined to sponsor + therapeutic area + drug class. Forward-looking forecast. Sourced from FDA Orange Book + USPTO Patent Public Search.

52 drugs 147 patents 12 therapeutic areas Forward-looking

By therapeutic area

Oncology (22)

2034-01-12 — Taxol · Pfizer · Microtubule Inhibitor [EPC] · Method of Use
2034-01-12 — Taxol · Pfizer · Microtubule Inhibitor
2034-02-02 — Estrace · Pfizer · Estrogen · Method of Use
2034-02-02 — Estring · Pfizer Inc. · Combined Oral Contraceptive (COC) · Method of Use
2034-02-07 — Sandimmune · Novartis · Calcineurin Inhibitor Immunosuppressant [EPC]
2034-02-11 — Xyosted (Autoinjector) · Endo · Androgen
2034-02-14 — Faslodex · AstraZeneca · Estrogen Receptor Antagonist [EPC] · Formulation
2034-02-17 — Xarelto · Johnson & Johnson · Direct Factor Xa Inhibitor · Method of Use
2034-03-13 — Elocon · Merck & Co. · Corticosteroid · Formulation
2034-03-14 — Mavyret · AbbVie · Hepatitis C Virus NS5A Inhibitor [EPC]
2034-03-17 — Zytiga · Johnson & Johnson · Cytochrome P450 17A1 Inhibitor
2034-04-22 — Brukinsa · Beigene Usa Inc · Kinase Inhibitor [EPC]
2034-05-12 — Cortef · Generic (originally Merck/Upjohn) · Corticosteroid [EPC] · Formulation
2034-05-12 — Cortifoam · Pfizer · Corticosteroid · Formulation
2034-05-12 — Solu-Cortef · Pfizer · Corticosteroid · Formulation
2034-05-23 — Decadron · Generic (originally Merck) · Corticosteroid [EPC] · Method of Use
2034-05-23 — Decadron-La · Merck & Co. · Corticosteroid · Method of Use
2034-06-17 — Lonsurf · Taiho Oncology Inc · Nucleoside Analog Antiviral [EPC]
2034-08-19 — Gemzar · Accord Hlthcare · Nucleoside metabolic inhibitor · Formulation
2034-10-17 — Pluvicto · Aaa Usa Novartis · Radioligand Therapeutic Agent [EPC]
2034-10-29 — Trexall · Generic (originally Lederle Laboratories) · Antifolate, DMARD · Formulation
2034-12-03 — Litfulo · Pfizer

Metabolic (8)

2034-02-02 — Femring · Apil · Estrogen · Method of Use
2034-03-14 — Keppra · Generic (originally UCB Pharma) · Antiepileptic agent · Formulation
2034-03-14 — Zosyn · Merck Sharp & Dohme B.V. · beta Lactamase Inhibitor
2034-04-03 — Tradjenta · Boehringer Ingelheim · Dipeptidyl Peptidase 4 Inhibitor [EPC]
2034-05-02 — Ozempic · Novo Nordisk · GLP-1 Receptor Agonist [EPC]
2034-06-15 — semaglutide or tirzepatide · Mayo Clinic · GLP-1 receptor agonist
2034-06-17 — Cystagon · Mylan · Cystine Depleting Agent
2034-12-20 — Zuragard · isopropanol

Neuroscience (5)

2034-01-08 — Ativan · Generic (originally Wyeth/Pfizer) · Benzodiazepine [EPC] · Formulation
2034-03-08 — Abilify · Generic (originally Otsuka/BMS) · Third-generation antipsychotic (D2 partial agonist) · Method of Use
2034-03-12 — Duramorph Pf · Pfizer · Opioid Agonist · Formulation
2034-04-23 — Phenergan Vc W/ Codeine · ANI Pharmaceuticals · Nonsteroidal Anti-inflammatory Drug [EPC]
2034-06-23 — Renacidin · Baxter · Anti-coagulant

Immunology (5)

2034-02-07 — Sandimmune · Novartis AG (originally Sandoz) · Calcineurin inhibitor (immunosuppressant) · Formulation
2034-02-24 — Cupric Sulfate · Abraxis Pharm · copper sulfate · Method of Use
2034-05-23 — Dexamethasone Sodium Phosphate · Merck & Co. · Corticosteroid · Method of Use
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · Complement Inhibitors · Method of Use
2034-09-02 — Cytovene · Roche Palo · Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor · Formulation

Pain (3)

2034-02-24 — Arnicare Leg Cramps · Sebela Womens Hlth · Copper-containing Intrauterine Device [EPC] · Method of Use
2034-03-12 — MS Contin · Generic (multiple manufacturers) · Opioid analgesic · Formulation
2034-07-18 — Naloxone Hydrochloride · Pfizer Inc. · Mixed opioid agonist-antagonist with opioid antagonist · Formulation

Infectious Disease (2)

2034-03-13 — Stromectol · Merck & Co. · Antiparasitic [EPC] · Method of Use
2034-03-14 — Zerbaxa · Cubist Pharms · Cephalosporin Antibacterial

Cardiovascular (2)

2034-04-03 — Lasix · Generic (originally Hoechst AG) · Loop Diuretic [EPC] · Method of Use
2034-06-19 — Camzyos · Myokardia Inc · Cardiac Myosin Inhibitor [EPC]

Ophthalmology (1)

2034-03-13 — Bupivacaine Hydrochloride · Pfizer · Amide-type local anesthetic

Nephrology (1)

2034-03-14 — Rayaldee · calcifediol · Formulation

Bone (1)

2034-03-22 — Jadelle · Fdn Consumer · Progestin · Formulation

Gastroenterology (1)

2034-06-23 — Prepopik · Baxter · magnesium oxide

Hematology (1)

2034-11-26 — Ferrlecit · Vifor Fresenius · Phosphate Binder [EPC]

Subscribe to patent-cliff alerts

Push every new patent expiry into your RSS reader:

Biosimilar tracker — who's competing for each post-cliff originator
Patent cliff revenue calculator
2034 patent expiries dataset (CSV / JSON)